OR WAIT null SECS
February 24, 2022
Janssen will pay upwards of $1 billion for exclusive rights to use Remix’s RNA-based drug discovery platform on three specific targets.
Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.
Taconic Biosciences Cage+ colony management service aims to offer comprehensive coverage for contract breeding services.
MilliporeSigma and Waters will work together to build an extractables and leachables (E&L) reference library.
Scottish Enterprise has awarded £20 million (US$27 million) to Valneva Scotland to advance vaccine development.
February 23, 2022
Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.
Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.
Sanofi and GSK announce they are seeking regulatory authorization for COVID-19 vaccine.
MHRA has opened a consultation on the proposed changes to clinical trial legislation in the UK.
Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.